Zhi Tong Cai Jing·2025-09-15 12:38Core Insights - Novartis has signed a collaboration agreement with Monte Rosa Therapeutics worth up to $5.7 billion to jointly develop drugs for immune-mediated diseases [1] - Monte Rosa will receive an upfront payment of $120 million and has the potential to earn additional revenue through milestone payments and sales royalties [1] - The agreement grants Novartis exclusive rights to an undisclosed drug discovery target and options for two additional projects from Monte Rosa's early immunology pipeline [1] Group 1 - Immune-mediated diseases involve the immune system mistakenly attacking healthy tissues, leading to inflammation and damage, significantly affecting patients' quality of life [1] - Monte Rosa will utilize its AI-driven platform to discover and develop new degraders, which are small molecules designed to break down pathogenic proteins, with Novartis advancing clinical development and commercialization [1] - This collaboration marks the second partnership between Novartis and Monte Rosa, following a previous agreement on MRT-6160, which is currently in early clinical trials for autoimmune and inflammatory diseases [1] Group 2 - This agreement is the second large transaction for Novartis this month, following a $5.2 billion collaboration with Argo Biopharmaceuticals to develop an experimental heart disease drug [2]